利妥昔单抗联合CHOP化疗方案治疗非霍奇金淋巴瘤

目的：观察用利妥昔单抗联合CHOP化疗方案和单用CHOP化疗方案治疗B细胞系CD20阳性非霍奇金淋巴瘤患者的疗效及不良反应。方法：共23例B细胞系非霍奇金淋巴瘤患者,11例（R-CHOP组）采用利妥昔单抗联合CHOP化疗方案,12例（CHOP组）单用CHOP化疗方案。结果：在R-CHOP组中,完全缓解（CR）7例,部分缓解（PR）2例,有效率为81.8%;在CHOP组中,CR2例,PR3例,有效率为41.7%,两组有显著差异（P〈0.05）。胃肠道反应的发生率R-CHOP组为18.2%,CHOP组为16.7%,两组无显著差异（P〉0.05）;白细胞减少的发生率R-CHOP组为36.4%,CHOP组为41.7%,两组无显著差异（P〉0.05）;发热的发生率R-CHOP组为45.5%,CHOP组为8.3%,两组有显著差异（P〈0.05）。结论：用利妥昔单抗联合CHOP方案治疗B细胞系CD20阳性非霍奇金淋巴瘤患者疗效较好;化疗最明显的不良反应是发热,患者可以耐受,它可以做为临床一线治疗方案。

The Clinical Study of Rituximab Combined CHOP in Treating B-cell Non-Hodgkin's Lymphoma

Objective：To observe the clinical effects and toxicities of Rituximab combined CHOP and CHOP alone on newly diagnosed patients with B-cell non-Hodgkin′s Lymphoma（NHL）.Methods： There were 23 patients of B-cell NHL in our study.11 patients accepted Rituximab combined CHOP chemotherapy.The others accepted CHOP chemotherapy.Results： The overall response rates were 81.8%in R-CHOP group and 41.7%in CHOP group.There were significant differences between them（P0.05）.The major side effects were gastrointestinal reaction,leucocytopenia and fever.The incidence rate of gastrointestinal reaction was 18.2% in R-CHOP group and 16.7%in CHOP group.There was no significant difference between them（P0.05）.The incidence rate of leucocytopenia was 36.4% in R-CHOP group and 41.7% in CHOP group.There were no significant differences between them（P0.05）.The incidence rate of fever was 45.5% in R-CHOP group and 8.3%in CHOP group.There was significant difference between them（P0.05）.Conclusions： Rituximab combined CHOP has good effeet on treating B-cell non-Hodgkin′s lymphoma.The major side effect is fever that can be acceptable.Rituximab combined CHOP can be used as the first line in clinic.